Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma

被引：6

作者：

Tiplady, CW ^{[2
]}

Summerfield, GP

机构：

[1] Queen Elizabeth Hosp, Dept Haematol, Gateshead, England

[2] Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2000年 / 111卷 / 01期

关键词：

multiple myeloma; dexamethasone;

D O I：

10.1046/j.1365-2141.2000.02372.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：381 / 381

页数：1

共 4 条

[1]

Kneller A, 2000, BRIT J HAEMATOL, V108, P391

[2] CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma [J].

Parameswaran, R ;

Giles, C ;

Boots, M ;

Littlewood, TJ ;

Mills, MJ ;

Kelsey, SM ;

Samson, D .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (03) :571-575

[3] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[4]

Tiplady C. W., 1997, British Journal of Haematology, V97, P23

← 1 →